PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 4, 2026Cancer Biology and Medicine0 citationsOpen Access

Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives

JYJing YuMLMaochen LiYZYuhan Zhu

Key Points

  • The aim is to explore the current clinical progress of PARP inhibitors for ovarian cancer and understand resistance mechanisms.
  • Review of global incidence and mortality rates of ovarian cancer.
  • Analysis of clinical studies on PARP inhibitors in ovarian cancer treatment.
  • Discussion of resistance mechanisms and potential future research directions.
  • Ovarian cancer incidence and mortality continue to rise, particularly in China.
  • Clinical use of PARP inhibitors shows promise but faces challenges due to resistance mechanisms.
  • Future perspectives suggest a need for personalized treatment strategies in ovarian cancer management.

Abstract

Ovarian cancer (OC) ranks eighth in incidence and mortality among female cancers11. The global annual incidence of new OC cases increased from 238,700 to 324,398, while deaths rose from 151,900 to 206,839 from 2012 to 2022, respectively11,22. China reported the highest global numbers of

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/6a2115bdd499ed480b16eb3fhttps://doi.org/10.20892/j.issn.2095-3941.2026.0102
Ask AI
Helpful
Bookmark
Share
View Full Paper